BSE Sensex: (9902) we said that ‘Crucial support once again to watch would be 9520’. The market has not breached the crucial supports and has stayed put and the market is still in a ‘sell mode’ despite closing positive. ...
Read More..
Quotes with Resistance & Support
Market Information
Market Review for 2nd April 2009
Posted on: Wednesday, April 1st 2009 and is filed under Market Outlook.
Buy Reliance Communication, target of Rs 250: IIFL
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
IIFL has recommended a buy rating on Reliance Communication with a target price of Rs 250 in its March 31, 2009 research report. “RCOM’s execution skills will come into focus now that regulatory churn has subsided. The company has got off to a smart start with its wireless broadba...
Read More..
Read More..
Tata Chemicals an outperformer: Karvy Stock Broking
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Karvy Stock Broking has maintained its outperformer rating on Tata Chemicals with a price target of Rs Rs 166 in its April 1, 2009 research report. Tata Chemicals formally signed gas sale and purchase agreements (GSPA) with Reliance Industries (RIL) on March 27 2009. ...
Read More..
Read More..
Accumulate RIL, target of Rs 1558: Prabhudas Lilladher
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Prabhudas Lilladher has recommended an accumulate rating on Reliance Industries with a price target of Rs 1558 in its March 2009 research report. “RIL’s two biggest projects (RPL refinery and KG D6 gas production) are going on-stream from April 2009. ...
Read More..
Read More..
Buy Cadila Healthcare, target of Rs 372: Sharekhan
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Sharekhan has maintained its buy rating on Cadila Healthcare with a price target of Rs 372 in its March 31, 2009 research report. “Zydus Cadila (Zydus) has signed a new collaborative drug discovery and development deal with US-based Eli Lilly to develop drugs focusing on the area of...
Read More..
Read More..
Buy Bartronics India, target of Rs 95: Sunidhi Securities
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Sunidhi Securities & Finance has recommended a buy rating on Bartronics India with a target price of Rs 95 in its April 1, 2009 research report. “BIL has bagged the prestigious project “AapKe Dwar” project from the Municipal Corporation of Delhi. ...
Read More..
Read More..
Buy Great Offshore, target of Rs 376: Reliance Money
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Reliance Money has maintained its buy rating on Great Offshore with a target price of Rs 376 in its April 1, 2009 research report. “Great Offshore Limited has bagged a 3 year charter commencing end April 2009 with ONGC for three of its vessels (1 PSV and 2 AHTSVs) for operating in ...
Read More..
Read More..
Buy Jindal Saw, target of Rs 476: Sharekhan
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Sharekhan has maintained its buy rating on Jindal Saw with a price target of Rs 476 in its March 31, 2009 research report. “Jindal Saw Ltd’s (JSL) Q4CY2008 numbers are ahead of our expectations on the back of an exceptionally strong top line. With the hive-off of the US division, ...
Read More..
Read More..
Buy Cadila Healthcare, target of Rs 350: Angel Broking
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
Angel Broking has maintained its buy rating on Cadila Healthcare with a target price of Rs 350 in its March 30, 2009 research report. “We believe Cadila’s R&D collaboration deal with Eli Lilly is a positive as it corroborates Cadila’s capabilities, although material cash fl...
Read More..
Read More..
Buy Ranbaxy Laboratories, target of Rs 183: KRChoksey
Posted on: Wednesday, April 1st 2009 and is filed under Brokerage Recommendations.
KRChoksey has maintained its buy rating on Ranbaxy Laboratories with a price target of Rs 183 in its April 1, 2009 research report. “Ranbaxy to launch Daiichi Sankyo’s innovative antihypertensive drug, “Olvance” in India. We have revised our earnings estimate keeping in view t...
Read More..
Read More..
Latest Query
Samrudhiglobal.com wishing you and your friends and family Advance xmas and Happy New year...view more »
- by Sam
- by Sam
Status: Awaiting reply
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
